{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T14:25:40Z","timestamp":1761575140567,"version":"build-2065373602"},"reference-count":55,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["16\/81\/01"],"award-info":[{"award-number":["16\/81\/01"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"<jats:sec id=\"abs1-1\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Motor neuron disease is a progressive, fatal neurodegenerative disease for which there is no cure. Formal psychological therapies are not routinely part of United Kingdom standard motor neuron disease care due to a lack of evidence-based guidance resulting from a paucity of clinical trials. We aimed to evaluate the clinical and cost-effectiveness of Acceptance and Commitment Therapy plus usual care compared to usual care alone for improving psychological health in people living with motor neuron disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-2\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted qualitative interviews with 15 people living with motor neuron disease, 10 caregivers and 12 healthcare professionals. Findings were used to develop an Acceptance and Commitment Therapy intervention specifically for people living with motor neuron disease. Next, we examined its acceptability and feasibility in an uncontrolled feasibility study with 29 people living with motor neuron disease. Findings from qualitative interviews with 14 people living with motor neuron disease and 11 therapists were used to revise the intervention. Finally, we conducted a multicentre, parallel, two-arm randomised controlled trial in 16 United Kingdom motor neuron disease care centres\/clinics. Eligible participants were aged\u2005\u2265\u200518 years with motor neuron disease. Participants were randomly assigned (1\u2005:\u20051) to receive up to eight sessions of Acceptance and Commitment Therapy plus usual care or usual care alone and followed up at 6 and 9 months post randomisation by blinded outcome assessors. The primary outcome was total score on the McGill Quality of Life Questionnaire-Revised at 6 months. Secondary outcomes included health status using the EuroQol-5 Dimensions, five-level version. Primary analyses were by intention to treat.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-3\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Acceptance and Commitment Therapy was acceptable to people living with motor neuron disease, and it was feasible to recruit participants, hence trial progression criteria were met. From September 2019 to August 2022, 191 participants were recruited: 97 were allocated to Acceptance and Commitment Therapy plus usual care and 94 to usual care alone. Mean age was 61.9 years (standard deviation 11.4), 58% were male and 95% were White\/White British. Acceptance and Commitment Therapy plus usual care was superior to usual care alone on the McGill Quality of Life Questionnaire-Revised at 6 months [adjusted mean difference 0.66 (95% confidence interval 0.22 to 1.10); Cohen\u2019s\n                      <jats:italic>d<\/jats:italic>\n                      \u2005=\u20050.46 (95% confidence interval 0.16 to 0.77);\n                      <jats:italic>p<\/jats:italic>\n                      \u2005=\u20050.003] and 9 months [adjusted mean difference 0.76 (95% confidence interval 0.30 to 1.22); Cohen\u2019s\n                      <jats:italic>d<\/jats:italic>\n                      \u2005=\u20050.53 (95% confidence interval 0.21 to 0.85);\n                      <jats:italic>p<\/jats:italic>\n                      \u2005=\u20050.001]. Mean differences in total costs and quality-adjusted life-years at 9 months between Acceptance and Commitment Therapy plus usual care versus usual care alone were not statistically significant [costs: \u00a31019 (95% confidence interval \u2212\u00a334 to \u00a32074); quality-adjusted life-years: 0.019 (95% confidence interval \u22120.07 to 0.05)]. The incremental cost-effectiveness ratio was \u00a388,507\/quality-adjusted life-year: this decreased to \u00a313,817\/quality-adjusted life-year in those with medium disease-related deterioration in subgroup analyses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-4\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Acceptance and Commitment Therapy plus usual care is clinically effective at maintaining or improving psychological health, as measured by the McGill Quality of Life Questionnaire-Revised, in people living with motor neuron disease compared to usual care alone. It was not cost-effective overall when calculated using a standard health status measure (EuroQol-5 Dimensions, five-level version). However, it was cost-effective in a subgroup of people experiencing a medium rate of disease-related deterioration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-5\">\n                    <jats:title>Limitations<\/jats:title>\n                    <jats:p>Participants from ethnic minorities were under-represented, despite recruiting from sites with diverse communities. Between-group differences in outcomes may have been partly attributable to expectancy or non-specific therapeutic effects due to the lack of an active control. Cost-effectiveness analyses may have been underpowered to detect significant between-group differences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-6\">\n                    <jats:title>Future work<\/jats:title>\n                    <jats:p>Studies should examine the effectiveness of Acceptance and Commitment Therapy in diverse populations, compared to an active control, using a more appropriate measure to assess cost-effectiveness, and in those with different rates of disease-related deterioration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-7\">\n                    <jats:title>Funding<\/jats:title>\n                    <jats:p>This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number 16\/81\/01.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3310\/jhgd7339","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T04:56:36Z","timestamp":1736484996000},"page":"1-28","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Acceptance and Commitment Therapy for people living with motor neuron disease: the COMMEND feasibility study and randomised controlled trial"],"prefix":"10.3310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9283-1626","authenticated-orcid":true,"given":"Rebecca L","family":"Gould","sequence":"first","affiliation":[{"name":"Division of Psychiatry, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5516-8797","authenticated-orcid":true,"given":"Benjamin J","family":"Thompson","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2042-0203","authenticated-orcid":true,"given":"Charlotte V","family":"Rawlinson","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6519-3558","authenticated-orcid":true,"given":"Matt","family":"Bursnall","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3783-9761","authenticated-orcid":true,"given":"Mike","family":"Bradburn","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8889-6806","authenticated-orcid":true,"given":"Anju D","family":"Keetharuth","sequence":"additional","affiliation":[{"name":"Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-0471","authenticated-orcid":true,"given":"Tracey","family":"Young","sequence":"additional","affiliation":[{"name":"Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7852-2018","authenticated-orcid":true,"given":"Vanessa","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Department of Health Services & Population Research, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2871-7946","authenticated-orcid":true,"given":"David A","family":"White","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3071-2338","authenticated-orcid":true,"given":"Robert J","family":"Howard","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8388-0776","authenticated-orcid":true,"given":"Marc A","family":"Serfaty","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9734-0153","authenticated-orcid":true,"given":"Lance M","family":"McCracken","sequence":"additional","affiliation":[{"name":"Department of Psychology, Uppsala University, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8456-9154","authenticated-orcid":true,"given":"Christopher D","family":"Graham","sequence":"additional","affiliation":[{"name":"Department of Psychological Sciences & Health, University of Strathclyde, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4924-7712","authenticated-orcid":true,"given":"Ammar","family":"Al-Chalabi","sequence":"additional","affiliation":[{"name":"Maurice Wohl Clinical Neuroscience Institute, King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9387-3035","authenticated-orcid":true,"given":"Laura H","family":"Goldstein","sequence":"additional","affiliation":[{"name":"Department of Psychology, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2255-1166","authenticated-orcid":true,"given":"Dynameni","family":"Androulaki-Koraki","sequence":"additional","affiliation":[{"name":"Department of Health Services & Population Research, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9649-9296","authenticated-orcid":true,"given":"Pavithra","family":"Kumar","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5206-266X","authenticated-orcid":true,"given":"Kirsty","family":"Weeks","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1435-9474","authenticated-orcid":true,"given":"Rebecca","family":"Gossage-Worrall","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5763-9604","authenticated-orcid":true,"given":"Emily J","family":"Turton","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6303-9610","authenticated-orcid":true,"given":"Simon","family":"Waterhouse","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6177-0285","authenticated-orcid":true,"given":"Nicola","family":"Drewry","sequence":"additional","affiliation":[{"name":"Patient and Public Involvement representative"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2995-5447","authenticated-orcid":true,"given":"Cindy","family":"Cooper","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8925-2567","authenticated-orcid":true,"given":"Pamela J","family":"Shaw","sequence":"additional","affiliation":[{"name":"Sheffield Institute for Translational Neuroscience, and the NIHR Sheffield Biomedical Research Centre, University of Sheffield, Sheffield, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8598-7454","authenticated-orcid":true,"given":"Christopher J","family":"McDermott","sequence":"additional","affiliation":[{"name":"Sheffield Institute for Translational Neuroscience, and the NIHR Sheffield Biomedical Research Centre, University of Sheffield, Sheffield, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6221","published-online":{"date-parts":[[2025,10]]},"reference":[{"key":"key2025102718390300_ref1-bib1","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S1474-4422(21)00465-8","article-title":"Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis","volume":"21","author":"Goutman","year":"2022","journal-title":"Lancet Neurol"},{"key":"key2025102718390300_ref2-bib2","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001447.pub2","article-title":"Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND)","volume":"1","author":"Miller","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"key2025102718390300_ref3-bib3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jad.2021.03.015","article-title":"Prevalence of depression among amyotrophic lateral sclerosis (ALS) patients: a systematic review and meta-analysis","volume":"287","author":"Heidari","year":"2021","journal-title":"J Affect Disord"},{"key":"key2025102718390300_ref4-bib4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/00023210-200721040-00003","article-title":"Depression and anxiety in individuals with amyotrophic lateral sclerosis: epidemiology and management","volume":"21","author":"Kurt","year":"2007","journal-title":"CNS Drugs"},{"key":"key2025102718390300_ref5-bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1001\/archneur.1994.00540130027010","article-title":"Survival in amyotrophic lateral sclerosis. The role of psychological factors","volume":"51","author":"McDonald","year":"1994","journal-title":"Arch Neurol"},{"key":"key2025102718390300_ref6-bib6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1348\/135910799168524","article-title":"Mood as a predictor of disability and survival in patients newly diagnosed with ALS\/MND","volume":"4","author":"Johnston","year":"1999","journal-title":"Br J Health Psychol"},{"key":"key2025102718390300_ref7-bib7","first-page":"115","article-title":"Depression, pain and quality of life in patients with amyotrophic lateral sclerosis: a cross-sectional study","volume":"28","author":"Pizzimenti","year":"2013","journal-title":"Funct Neurol"},{"key":"key2025102718390300_ref8-bib8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12955-016-0507-6","article-title":"Associations between psychological factors and health-related quality of life and global quality of life in patients with ALS: a systematic review","volume":"14","author":"van Groenestijn","year":"2016","journal-title":"Health Qual Life Outcomes"},{"key":"key2025102718390300_ref9-bib9","doi-asserted-by":"crossref","first-page":"423","DOI":"10.4172\/2155-9562.1000423","article-title":"Functional decline is associated with hopelessness in amyotrophic lateral sclerosis (ALS)","volume":"8","author":"Paganoni","year":"2017","journal-title":"J Neurol Neurophysiol"},{"key":"key2025102718390300_ref10-bib10","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3109\/21678421.2015.1062515","article-title":"Psychotherapy and pharmacotherapy interventions to reduce distress or improve well-being in people with amyotrophic lateral sclerosis: a systematic review","volume":"16","author":"Gould","year":"2015","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"key2025102718390300_ref11-bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21678421.2020.1788094","article-title":"Psychological interventions for people with motor neuron disease: a scoping review","volume":"22","author":"Zarotti","year":"2021","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"key2025102718390300_ref12-bib12","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/ene.13246","article-title":"Meditation training for people with amyotrophic lateral sclerosis: a randomized clinical trial","volume":"24","author":"Pagnini","year":"2017","journal-title":"Eur J Neurol"},{"key":"key2025102718390300_ref13-bib13","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1080\/21678421.2021.1928707","article-title":"An online non-meditative mindfulness intervention for people with ALS and their caregivers: a randomized controlled trial","volume":"23","author":"Pagnini","year":"2022","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"key2025102718390300_ref14-bib14","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3109\/21678421.2015.1038276","article-title":"Cognitive behavioural therapy and quality of life in psychologically distressed patients with amyotrophic lateral sclerosis and their caregivers: results of a prematurely stopped randomized controlled trial","volume":"16","author":"van Groenestijn","year":"2015","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"key2025102718390300_ref15-bib15","volume-title":"Motor Neurone Disease: Assessment and Management (NG42)","author":"National Institute for Health and Care Excellence","year":"2016"},{"key":"key2025102718390300_ref16-bib16","doi-asserted-by":"crossref","DOI":"10.1037\/17335-000","volume-title":"Acceptance and Commitment Therapy: The Process and Practice of Mindful Change","author":"Hayes","year":"2012"},{"key":"key2025102718390300_ref17-bib17","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1017\/S0033291722000083","article-title":"A randomised controlled trial of acceptance and commitment therapy for improving quality of life in people with muscle diseases","volume":"53","author":"Rose","year":"2023","journal-title":"Psychol Med"},{"key":"key2025102718390300_ref18-bib18","doi-asserted-by":"crossref","first-page":"e057212","DOI":"10.1136\/bmj-2021-057212","article-title":"New generation psychological treatments in chronic pain","volume":"376","author":"McCracken","year":"2022","journal-title":"BMJ"},{"key":"key2025102718390300_ref19-bib19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jcbs.2020.09.009","article-title":"The empirical status of acceptance and commitment therapy: a review of meta-analyses","volume":"18","author":"Gloster","year":"2020","journal-title":"J Contextual Behav Sci"},{"key":"key2025102718390300_ref20-bib20","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1186\/s12883-022-02950-5","article-title":"A randomised controlled trial of acceptance and commitment therapy plus usual care compared to usual care alone for improving psychological health in people with motor neuron disease (COMMEND): study protocol","volume":"22","author":"Gould","year":"2022","journal-title":"BMC Neurol"},{"key":"key2025102718390300_ref21-bib21","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/21678421.2019.1621344","article-title":"Needs and preferences for psychological interventions of people with motor neuron disease","volume":"20","author":"Weeks","year":"2019","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"key2025102718390300_ref22-bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40814-023-01354-7","article-title":"Acceptance and Commitment Therapy for people living with motor neuron disease: an uncontrolled feasibility study","volume":"9","author":"Gould","year":"2023","journal-title":"Pilot Feasibility Stud"},{"key":"key2025102718390300_ref23-bib23","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1017\/S1754470X24000333","article-title":"Experiences of acceptance and commitment therapy for people living with motor neuron disease (MND): a qualitative study from the perspective of people living with MND and therapists","volume":"17","author":"Rawlinson","year":"2024","journal-title":"Cogn Behav Ther"},{"key":"key2025102718390300_ref24-bib24","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1016\/S0140-6736(24)00533-6","article-title":"Acceptance and Commitment Therapy plus usual care for improving quality of life in people with motor neuron disease (COMMEND): a multicentre, parallel, randomised controlled trial in the UK","volume":"403","author":"Gould","year":"2024","journal-title":"Lancet"},{"key":"key2025102718390300_ref25-bib25","doi-asserted-by":"crossref","first-page":"e16317","DOI":"10.1111\/ene.16317","article-title":"Cost\u2010effectiveness of acceptance and commitment therapy for people living with motor neuron disease, and their health\u2010related quality of life","volume":"31","author":"Keetharuth","year":"2024","journal-title":"Eur J Neurol"},{"key":"key2025102718390300_ref26-bib26","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000365764","article-title":"A meta-analysis of the efficacy of acceptance and commitment therapy for clinically relevant mental and physical health problems","volume":"84","author":"A-Tjak","year":"2015","journal-title":"Psychother Psychosom"},{"key":"key2025102718390300_ref27-bib27","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.MLR.0000062554.74615.4C","article-title":"Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation","volume":"41","author":"Norman","year":"2003","journal-title":"Med Care"},{"key":"key2025102718390300_ref28-bib28","volume-title":"Index of Multiple Deprivation (IMD) | CDRC Data","author":"Consumer Data Research Centre","year":"2019"},{"key":"key2025102718390300_ref29-bib29","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/21678421.2021.2016837","article-title":"Analysis of incidence of motor neuron disease in England 1998\u20132019: use of three linked datasets","volume":"23","author":"Burchardt","year":"2022","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"key2025102718390300_ref30-bib30","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jclinepi.2020.05.001","article-title":"Treatment effects may remain the same even when trial participants differed from the target population","volume":"124","author":"Bradburn","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"key2025102718390300_ref31-bib31","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jpain.2019.05.012","article-title":"Physical therapy informed by acceptance and commitment therapy (PACT) versus usual care physical therapy for adults with chronic low back pain: a randomized controlled trial","volume":"21","author":"Godfrey","year":"2020","journal-title":"J Pain"},{"key":"key2025102718390300_ref32-bib32","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jcbs.2022.05.005","article-title":"Acceptance and commitment therapy informed behavioral health interventions delivered by non-mental health professionals: a systematic review","volume":"24","author":"Arnold","year":"2022","journal-title":"J Contextual Behav Sci"},{"key":"key2025102718390300_ref33-bib33","volume-title":"Good Practice Guidelines on the Recruitment and Involvement of Public Members on Trial Steering Committees (TSCs)\/Study Steering Committees (SSCs)","author":"National Institute for Health and Care Research","year":"2021"},{"key":"key2025102718390300_ref34-bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-0327(01)00379-2","article-title":"Barriers to help-seeking by men: a review of sociocultural and clinical literature with particular reference to depression","volume":"71","author":"M\u00f6ller-Leimk\u00fchler","year":"2002","journal-title":"J Affect Disord"},{"key":"key2025102718390300_ref35-bib35","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.cpr.2016.09.002","article-title":"The role of masculinity in men\u2019s help-seeking for depression: a systematic review","volume":"49","author":"Seidler","year":"2016","journal-title":"Clin Psychol Rev"},{"key":"key2025102718390300_ref36-bib36","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1212\/WNL.0b013e3181a55f7b","article-title":"Reduced frequency of ALS in an ethnically mixed population: a population-based mortality study","volume":"72","author":"Zaldivar","year":"2009","journal-title":"Neurology"},{"key":"key2025102718390300_ref37-bib37","first-page":"57","article-title":"Variation in world wide incidence of amyotrophic lateral sclerosis: a meta-analysis","volume":"46","author":"Marin","year":"2017","journal-title":"Int J Epidemiol"},{"key":"key2025102718390300_ref38-bib38","volume-title":"Ethnicity Facts and Figures. Office for National Statistics","author":"Office for National Statistics","year":"2020"},{"key":"key2025102718390300_ref39-bib39","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1080\/13854046.2023.2215491","article-title":"A retrospective analysis of the ethnicity of individuals referred to a tertiary neuropsychology service in the United Kingdom","volume":"38","author":"Teager","year":"2023","journal-title":"Clin Neuropsychol"},{"key":"key2025102718390300_ref40-bib40","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1037\/a0026235","article-title":"Exploring cultural competence in acceptance and commitment therapy outcomes","volume":"43","author":"Woidneck","year":"2012","journal-title":"Prof Psychol Res Pr"},{"key":"key2025102718390300_ref41-bib41","doi-asserted-by":"crossref","first-page":"e0166599","DOI":"10.1371\/journal.pone.0166599","article-title":"A randomized controlled trial of acceptance and commitment therapy for type 2 diabetes management: the moderating role of coping styles","volume":"11","author":"Shayeghian","year":"2016","journal-title":"PLOS ONE"},{"key":"key2025102718390300_ref42-bib42","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mpr.1434","article-title":"Barriers to recruiting ethnic minorities to mental health research: a systematic review","volume":"23","author":"Brown","year":"2014","journal-title":"Int J Methods Psychiatr Res"},{"key":"key2025102718390300_ref43-bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-020-04613-7","article-title":"Developing a roadmap to improve trial delivery for under-served groups: results from a UK multi-stakeholder process","volume":"21","author":"Witham","year":"2020","journal-title":"Trials"},{"key":"key2025102718390300_ref44-bib44","volume-title":"Improving Inclusion of Under-served Groups in Clinical Research: Guidance from the NIHR INCLUDE Project","author":"National Institute for Health and Clinical Excellence","year":"2020"},{"key":"key2025102718390300_ref45-bib45","volume-title":"The Design and Conduct of Meaningful Experiments Involving Human Participants: 25 Scientific Principles","author":"Bausell","year":"2015"},{"key":"key2025102718390300_ref46-bib46","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10742-024-00327-4","article-title":"Practical challenges in mediation analysis: a guide for applied researchers","volume":"25","author":"Schuler","year":"2024","journal-title":"Health Serv Outcomes Res Methodol"},{"key":"key2025102718390300_ref47-bib47","doi-asserted-by":"crossref","first-page":"25152459211047227","DOI":"10.1177\/25152459211047227","article-title":"The failings of conventional mediation analysis and a design-based alternative","volume":"4","author":"Bullock","year":"2021","journal-title":"Adv Methods Pract Psychol Sci"},{"key":"key2025102718390300_ref48-bib48","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.brat.2011.05.005","article-title":"A talking control for use in evaluating the effectiveness of cognitive-behavioral therapy","volume":"49","author":"Serfaty","year":"2011","journal-title":"Behav Res Ther"},{"key":"key2025102718390300_ref49-bib49","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1037\/a0035036","article-title":"Mindfulness-based cognitive therapy for preventing relapse in recurrent depression: a randomized dismantling trial","volume":"82","author":"Williams","year":"2014","journal-title":"J Consult Clin Psychol"},{"key":"key2025102718390300_ref50-bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2021\/6681554","article-title":"Psychometric properties of preference-based measures for economic evaluation in amyotrophic lateral sclerosis: a systematic review","volume":"2021","author":"Peters","year":"2021","journal-title":"Neurol Res Int"},{"key":"key2025102718390300_ref51-bib51","volume-title":"NICE Health Technology Evaluations: The Manual","author":"National Institute for Health and Care Excellence","year":"2022"},{"key":"key2025102718390300_ref52-bib52","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40273-017-0544-y","article-title":"International regulations and recommendations for utility data for health technology assessment","volume":"35","author":"Rowen","year":"2017","journal-title":"PharmacoEconomics"},{"key":"key2025102718390300_ref53-bib53","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12955-018-0857-3","article-title":"Review and critical appraisal of studies mapping from quality of life or clinical measures to EQ-5D: an online database and application of the MAPS statement","volume":"16","author":"Dakin","year":"2018","journal-title":"Health Qual Life Outcomes"},{"key":"key2025102718390300_ref54-bib54","author":"Dakin","journal-title":"HERC Database of Mapping Studies, Version 7.0 2019"},{"key":"key2025102718390300_ref55-bib55","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1080\/13284207.2022.2163158","article-title":"Effects of acceptance and commitment therapy on depressive symptoms, anxiety, pain intensity, quality of life, acceptance, and functional impairment in individuals with neurological disorders: a systematic review and meta-analysis","volume":"27","author":"Han","year":"2023","journal-title":"Clin Psychol"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2049000","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/sites\/journalslibrary\/files\/journal_data\/JHGD7339\/JHGD7339.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2049000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T13:20:32Z","timestamp":1761571232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/JHGD7339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":55,"alternative-id":["10.3310\/JHGD7339"],"URL":"https:\/\/doi.org\/10.3310\/jhgd7339","relation":{},"ISSN":["2046-4924"],"issn-type":[{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"12-2017","name":"contractual_start_date","label":"contractual_start_date","group":{"name":"article_history","label":"Article History"}},{"value":"11-2023","name":"editorial_review_begun","label":"editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"04-2025","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}